AP 5346
Alternative Names: AP5346; ASK-H03; Polymer-DACH platinum conjugate - PlasmaTech Biopharmaceuticals; ProLindacLatest Information Update: 05 Aug 2015
At a glance
- Originator University of London School of Pharmacy
- Developer PlasmaTech Biopharmaceuticals
- Class Antineoplastics; Platinum complexes
- Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cholangiocarcinoma; Colorectal cancer; Head and neck cancer; Ovarian cancer
Most Recent Events
- 31 Dec 2011 Phase-II clinical trials in Cholangiocarcinoma in Europe (IV)
- 01 Nov 2010 Phase-II clinical trials in Ovarian cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in France (IV) (EudraCT2010-020030-25)
- 21 Apr 2009 Pharmacokinetics data from a Preclinical trial presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009)